Angina News and Research

RSS

Angina is chest pain or discomfort that occurs when an area of your heart muscle doesn't get enough oxygen-rich blood. Angina may feel like pressure or squeezing in your chest. The pain also may occur in your shoulders, arms, neck, jaw, or back. It can feel like indigestion.

Low plasma CETP activity associated with increased risk of heart disease, says study

Although seen as a potential heart disease therapy, raising high-density lipoprotein (HDL) cholesterol levels by inhibiting activity of a transfer protein may not be effective, a new study suggests.

16 Dec 2009

Celebrex stops aspirin from doing its job effectively

Millions of Americans take Celebrex for arthritis or other pain. Many, if they are middle-aged or older, also take a low-dose aspirin tablet daily to reduce the risk of heart attack and stroke. Yet they may be getting little protection, because Celebrex keeps the aspirin from doing its job effectively, a new study suggests.

15 Dec 2009

Combination therapy improves overall survival in women with advanced breast cancer

In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).

14 Dec 2009

Italy's economically disadvantaged people have higher rates of hospitalization for ACSC disorders

Despite free public healthcare, Italy's poor are more likely to end up in hospital with avoidable conditions, new research shows. This pattern, reported today in the online open access journal BMC Public Health, mirrors findings from a number of different healthcare systems around the world, although to date fewer studies have been completed in Europe.

11 Dec 2009

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

In a large Phase III clinical trial, Tasigna (nilotinib capsules) demonstrated greater efficacy over Gleevec (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The new clinical data were just presented as a late breaking abstract at the 51st annual meeting of the American Society of Hematology (ASH), in New Orleans, Louisiana.

11 Dec 2009

Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated

Attached is a press release issued earlier this morning by GlaxoSmithKline, announcing that GSK has initiated its second pivotal Phase 3 trial to evaluate the efficacy of long-term treatment with the investigational Lp-PLA2 inhibitor darapladib in men and women with acute coronary syndrome (ACS).

10 Dec 2009

Geisinger installs catheter-based cardiac assist device, Impella 2.5

A minimally invasive, catheter-based cardiac assist device - the Impella 2.5 - is credited with saving the life of 86-year-old Rose Lombardo of Hazleton. Grandmother to seven and great-grandmother to another 12, Rose was "at death's door" after suffering concurrent heart attacks, according to her daughter, Gabriella Norgard.

8 Dec 2009

Updated results from MYTHOS clinical trial of RenalGuard presented at AHA meeting

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that updated results from the MYTHOS investigator-sponsored clinical trial of RenalGuard(®) were presented at the American Heart Association (AHA) Scientific Sessions 2009, on Sunday, November 15 in Orlando, Florida.

2 Dec 2009

European Commission and the EMEA approve Angiox in primary PCI for STEMI

The Medicines Company announced today that it has received European approval for the use of Angiox® (bivalirudin) as an anticoagulant in patients with heart attacks (so-called ST-segment elevation myocardial infarction (STEMI)) undergoing emergency heart procedures called primary percutaneous coronary intervention (PCI).

1 Dec 2009

Study reveals high levels of cardiac biomarkers in the blood of heart attack patients

Many heart attack patients have high levels of cardiac biomarkers in the blood for several months after leaving the hospital, with more shortness of breath and chest pain, according to a Henry Ford Hospital study.

24 Nov 2009

New Drug Application for ticagrelor submitted to the FDA

AstraZeneca today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS).

23 Nov 2009

NHLBI-supported research shares new strategies on hypertension, heart defect and air pollution

New education strategies for better controlling hypertension and research suggesting a possible link between short-term and long-term exposure to air pollution and increased risk of constricted blood vessels are among the research highlights from studies supported by the National Heart, Lung, and Blood Institute (NHLBI) at the American Heart Association's 2009 Scientific Sessions in Orlando held Nov. 14-18.

20 Nov 2009

Data from second positive pivotal study of PSD502 for treatment of PE presented

At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora")., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).

20 Nov 2009

Positive results from Sciele Pharma's second pivotal study of PSD502 for the treatment of PE

At the annual meeting of the Sexual Medicine Society of North America, Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC, today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).

19 Nov 2009

CRESTOR reduces major cardiovascular events in women by 46%

A new analysis of the JUPITER trial, released today at the American Heart Association meeting in Orlando, Florida, demonstrates that CRESTOR (rosuvastatin calcium) 20mg reduced first major cardiovascular events by 46%.

18 Nov 2009

First gene expression test for coronary artery disease

The Heart & Vascular Center of Arizona today announced the availability of Corus(TM) CAD, the first and only gene expression test to quantify the likelihood of obstructive(i) coronary artery disease (CAD) in patients with stable chest pain.

18 Nov 2009

Transplanting people's own stem cells into heart muscle lessens pain and improves ability to walk

The largest national stem cell study for heart disease showed the first evidence that transplanting a potent form of adult stem cells into the heart muscle of subjects with severe angina results in less pain and an improved ability to walk. The transplant subjects also experienced fewer deaths than those who didn't receive stem cells.

18 Nov 2009

ECR Pharmaceuticals to commercialize and manufacture ZolpiMist in the U.S. and Canada

NovaDel Pharma Inc. today announced its entry into an exclusive license and distribution agreement with ECR Pharmaceuticals Company, Inc., a wholly owned subsidiary of Hi-Tech Pharmacal Co., Inc. to commercialize and manufacture ZolpiMist™ in the United States and Canada. ZolpiMist™ is our oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.

16 Nov 2009

Addrenex Pharmaceuticals to be acquired by Sciele Pharma

Sciele Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd. and Addrenex Pharmaceuticals, Inc., a privately-held U.S. pharmaceutical company specializing in developing drugs that regulate the adrenergic system, today announced that Sciele has agreed to acquire Addrenex.

16 Nov 2009

Aspirin doses have beneficial effects for patients with heart diorders: Study

On Sunday, November 15, 2009, Florida Atlantic University (FAU) researcher Charles H. Hennekens, M.D., the first Sir Richard Doll Research Professor in the Charles E. Schmidt College of Biomedical Science will present at the American Heart Association's Annual Scientific Sessions meeting in Orlando, FL, the first data in humans to show that all doses of aspirin used in clinical practice increase nitric oxide.

16 Nov 2009

Angina News and Research

Further Reading

Low plasma CETP activity associated with increased risk of heart disease, says study

Celebrex stops aspirin from doing its job effectively

Combination therapy improves overall survival in women with advanced breast cancer

Italy's economically disadvantaged people have higher rates of hospitalization for ACSC disorders

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated

Geisinger installs catheter-based cardiac assist device, Impella 2.5

Updated results from MYTHOS clinical trial of RenalGuard presented at AHA meeting

European Commission and the EMEA approve Angiox in primary PCI for STEMI

Study reveals high levels of cardiac biomarkers in the blood of heart attack patients

New Drug Application for ticagrelor submitted to the FDA

NHLBI-supported research shares new strategies on hypertension, heart defect and air pollution

Data from second positive pivotal study of PSD502 for treatment of PE presented

Positive results from Sciele Pharma's second pivotal study of PSD502 for the treatment of PE

CRESTOR reduces major cardiovascular events in women by 46%

First gene expression test for coronary artery disease

Transplanting people's own stem cells into heart muscle lessens pain and improves ability to walk

ECR Pharmaceuticals to commercialize and manufacture ZolpiMist in the U.S. and Canada

Addrenex Pharmaceuticals to be acquired by Sciele Pharma

Aspirin doses have beneficial effects for patients with heart diorders: Study

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News